CMG Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2001-08-01
- Employees
- 282
- Market Cap
- -
- Website
- http://www.cmgpharma.co.kr
Evaluate the Efficacy and Safety of CMG190303 in Patients with Type 2 Diabetes and Dyslipidemia
Phase 3
Recruiting
- Conditions
- Type 2 DiabetesDyslipidemia
- Interventions
- Drug: CMG190303(Dapagliflozin/Rosuvastatin)Drug: Rosuvastatin/Dapagliflozin placebo
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- CMG Pharmaceutical Co. Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT06772168
- Locations
- 🇰🇷
Buchon sejong hospital, Buchon, Korea, Republic of
🇰🇷Inje university heaundea paik hospital, Busan, Korea, Republic of
🇰🇷Soonchunhyang cheonan university hospital, Cheonan, Korea, Republic of
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- CMG Pharmaceutical Co. Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02501109
© Copyright 2025. All Rights Reserved by MedPath